NCT03374007 - Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

June 30, 2022

Study Completion Date

August 31, 2022

Conditions

Advanced Solid TumorRecurrent Solid TumorLymphomaRecurrent Lymphocyte Depleted Classical Hodgkin Lymphoma

Interventions

BIOLOGICAL

Geptanolimab Injection 1mg/kg

single-dose:1mg/kg

BIOLOGICAL

Geptanolimab Injection 3mg/kg

single-dose: 3mg/kg

BIOLOGICAL

Geptanolimab Injection 10mg/kg

single-dose:10mg/kg

BIOLOGICAL

Geptanolimab Injection 1mg/kg, q2w*6

multiple dosing: 1mg/kg, q2w\*6

BIOLOGICAL

Geptanolimab Injection 3mg/kg, q2w*6

multiple dosing: 3mg/kg, q2w\*6

BIOLOGICAL

Geptanolimab Injection 10mg/kg, , q2w*6

multiple dosing: 10mg/kg, , q2w\*6

BIOLOGICAL

Geptanolimab Injection 280mg, q3w

multiple dosing: 280mg, q3w

BIOLOGICAL

Geptanolimab Injection 3mg/kg, q2w

multiple dosing: 3mg/kg, q2w

Trial Locations (2)

NOT_YET_RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

RECRUITING

Harbin Medical University Cancer Hospital, Harbin